The estimated Net Worth of Steven R. King is at least 631 千$ dollars as of 17 May 2024. Steven King owns over 612 units of Jaguar Health Inc stock worth over 1,984$ and over the last 8 years he sold JAGX stock worth over 0$. In addition, he makes 628,677$ as Executive Vice President - Sustainable Supply、 Ethnobotanical Research and Intellectual Property and Secretary at Jaguar Health Inc.
Steven has made over 5 trades of the Jaguar Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 612 units of JAGX stock worth 692$ on 17 May 2024.
The largest trade he's ever made was exercising 13,333 units of Jaguar Health Inc stock on 5 April 2022 worth over 15,066$. On average, Steven trades about 746 units every 39 days since 2016. As of 17 May 2024 he still owns at least 1,756 units of Jaguar Health Inc stock.
You can see the complete history of Steven King stock trades at the bottom of the page.
Dr. Steven R. King Ph.D. serves as Executive Vice President - Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary of the Company. He was promoted to Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property in March 2020. From 2002 to 2014, Dr. King served as the Senior Vice President of Sustainable Supply, Ethnobotanical Research and Intellectual Property at our wholly-owned subsidiary, Napo Pharmaceuticals, Inc. Prior to that, Dr. King served as the Vice President of Ethnobotany and Conservation at Shaman Pharmaceuticals, Inc. Dr. King has been recognized by the International Natural Products and Conservation Community for the creation and dissemination of research on the long-term sustainable harvest and management of Croton lechleri, the widespread source of crofelemer. Dr. King is currently a member of the board of directors of Healing Forest Conservatory, a California not-for-profit public benefit corporation. Dr. King holds a Ph.D. in Biology from the Institute of Economic Botany of the New York Botanical Garden and an M.S. in Biology from the City University of New York.
As the Executive Vice President - Sustainable Supply、 Ethnobotanical Research and Intellectual Property and Secretary of Jaguar Health Inc, the total compensation of Steven King at Jaguar Health Inc is 628,677$. There are 1 executives at Jaguar Health Inc getting paid more, with Lisa Conte having the highest compensation of 1,433,160$.
Steven King is 62, he's been the Executive Vice President - Sustainable Supply、 Ethnobotanical Research and Intellectual Property and Secretary of Jaguar Health Inc since 2014. There are 4 older and 9 younger executives at Jaguar Health Inc. The oldest executive at Jaguar Health Inc is James Bochnowski, 76, who is the Independent Chairman of the Board.
Steven's mailing address filed with the SEC is C/O JAGUAR HEALTH, INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO, CA, 94104.
Over the last 9 years, insiders at Jaguar Health Inc have traded over 596,652$ worth of Jaguar Health Inc stock and bought 670,772 units worth 1,311,594$ . The most active insiders traders include Capital Partners, L.P.Sagar...、James J Bochnowski、Investments Ltd Burford Cap.... On average, Jaguar Health Inc executives and independent directors trade stock every 66 days with the average trade being worth of 27,901$. The most recent stock trade was executed by Pravin R Chaturvedi on 17 May 2024, trading 871 units of JAGX stock currently worth 984$.
jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
Jaguar Health Inc executives and other stock owners filed with the SEC include: